Drug Profile
Gemcitabine oral - INNOPHARMAX
Alternative Names: D07001; D07001-F4; Gemcitabine HCl - INNOPHARMAX; Inno-D07001Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator INNOPHARMAX
- Class Amines; Antineoplastics; Deoxyribonucleosides; Fluorinated hydrocarbons; Ketones; Pyrimidine nucleosides; Pyrimidines; Small molecules
- Mechanism of Action Antimetabolites; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Biliary cancer
- No development reported Gastrointestinal cancer; Solid tumours
- Discontinued Lymphoma
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Gastrointestinal-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan (PO, Capsule)
- 30 Dec 2022 Discontinued - Phase-I for Lymphoma (Late-stage disease, Second-line therapy or greater) in Taiwan (PO)
- 04 Oct 2021 InnoPharmax plans a phase II/III (Combination therapy, Second-line therapy, late-stage disease) trial for Biliary cancer in Taiwan (PO) (NCT05065957)